Cite
HARVARD Citation
Finlay, A. et al. (2022). Secukinumab improves the quality‐of‐life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open‐label study (SIGNATURE). JEADV clinical practice. 1 (3), pp. 207-218. [Online].